Lexicon Completes Enrollment in Pivotal Phase 3 HCM Trial, Data in Q1 2027
LXRX has more than doubled off its 52-week low of $1.
Summary
Lexicon has fully enrolled the pivotal Phase 3 SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline results expected in Q1 2027. The trial targets both obstructive and non-obstructive HCM, a sizable market with limited oral options. This marks a key de-risking step for the program—enrollment completion reduces operational uncertainty and sets a clear data catalyst. With a $1B market cap and a near-breakeven Q1, positive data could materially expand the sotagliflozin franchise beyond heart failure. The Q1 2027 readout is now the major binary event for the stock.
At the time of this announcement, LXRX was trading at $2.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.00 to $2.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.